Do analysts prefer CLLS or TELO?

Cellectis currently has a consensus price target of $7.00, indicating a potential upside of 105.88%. Given Cellectis' stronger consensus rating and higher possible upside, research analysts clearly believe Cellectis is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectis 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend FATE or TELO?

Fate Therapeutics currently has a consensus price target of $5.90, suggesting a potential upside of 153.22%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Fate Therapeutics is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate TELO or RNAC?

Cartesian Therapeutics has a consensus target price of $32.60, suggesting a potential upside of 224.70%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cartesian Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Do analysts rate YDES or TELO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, YDES or TELO?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio YD Bio N/A N/A N/A N/A N/A Telomir Pharmaceuticals N/A N/A -$10.41M -$0.91 N/A

Is YDES or TELO more profitable?

YD Bio's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets YD Bio N/A N/A N/A Telomir Pharmaceuticals N/A -102.70% -90.75%

Which has preferable earnings and valuation, AVXL or TELO?

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anavex Life Sciences N/A N/A -$46.38M -$0.39 N/A Telomir Pharmaceuticals N/A N/A -$10.41M -$0.91 N/A

Is AVXL or TELO more profitable?

Anavex Life Sciences' return on equity of -32.73% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Anavex Life Sciences N/A -32.73% -30.15% Telomir Pharmaceuticals N/A -102.70% -90.75%

Telomir Pharmaceuticals (TELO) Competitors

$1.13 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

TELO vs. CLLS, FATE, RNAC, YDES, and AVXL

Should you buy Telomir Pharmaceuticals stock or one of its competitors? Telomir Pharmaceuticals's main competitors and comparable companies include Cellectis (CLLS), Fate Therapeutics (FATE), Cartesian Therapeutics (RNAC), YD Bio (YDES), and Anavex Life Sciences (AVXL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Telomir Pharmaceuticals compare to Cellectis?

Cellectis (NASDAQ:CLLS) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Cellectis has a beta of 2.91, suggesting that its share price is 191% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.24, suggesting that its share price is 124% less volatile than the broader market.

63.9% of Cellectis shares are owned by institutional investors. 16.4% of Cellectis shares are owned by company insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Telomir Pharmaceuticals has a net margin of 0.00% compared to Cellectis' net margin of -102.34%. Cellectis' return on equity of -94.19% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-102.34%	-94.19%	-21.34%
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%

Telomir Pharmaceuticals has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	4.29	-$67.59M	-$0.65	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A

Cellectis currently has a consensus price target of $7.00, indicating a potential upside of 105.88%. Given Cellectis' stronger consensus rating and higher possible upside, research analysts clearly believe Cellectis is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cellectis had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 1 mentions for Cellectis and 0 mentions for Telomir Pharmaceuticals. Cellectis' average media sentiment score of 0.30 beat Telomir Pharmaceuticals' score of 0.00 indicating that Cellectis is being referred to more favorably in the media.

Company	Overall Sentiment
Cellectis	Neutral
Telomir Pharmaceuticals	Neutral

Summary

Cellectis beats Telomir Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Fate Therapeutics?

Fate Therapeutics (NASDAQ:FATE) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

97.5% of Fate Therapeutics shares are owned by institutional investors. 4.7% of Fate Therapeutics shares are owned by insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Telomir Pharmaceuticals has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,941.09%. Fate Therapeutics' return on equity of -65.08% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-1,941.09%	-65.08%	-41.73%
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%

Fate Therapeutics currently has a consensus price target of $5.90, suggesting a potential upside of 153.22%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Fate Therapeutics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Fate Therapeutics has a beta of 2.52, meaning that its share price is 152% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.24, meaning that its share price is 124% less volatile than the broader market.

Telomir Pharmaceuticals has lower revenue, but higher earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.49M	43.01	-$136.32M	-$1.05	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A

In the previous week, Fate Therapeutics had 3 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 3 mentions for Fate Therapeutics and 0 mentions for Telomir Pharmaceuticals. Fate Therapeutics' average media sentiment score of 0.66 beat Telomir Pharmaceuticals' score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Fate Therapeutics	Positive
Telomir Pharmaceuticals	Neutral

Summary

Fate Therapeutics beats Telomir Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Cartesian Therapeutics?

Telomir Pharmaceuticals (NASDAQ:TELO) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Cartesian Therapeutics has a consensus target price of $32.60, suggesting a potential upside of 224.70%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Telomir Pharmaceuticals has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%

87.0% of Cartesian Therapeutics shares are held by institutional investors. 16.4% of Telomir Pharmaceuticals shares are held by insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Telomir Pharmaceuticals has higher earnings, but lower revenue than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A
Cartesian Therapeutics	$2.80M	108.47	-$130.30M	-$5.94	N/A

Telomir Pharmaceuticals has a beta of -0.24, suggesting that its share price is 124% less volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

In the previous week, Cartesian Therapeutics had 3 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 3 mentions for Cartesian Therapeutics and 0 mentions for Telomir Pharmaceuticals. Cartesian Therapeutics' average media sentiment score of 0.20 beat Telomir Pharmaceuticals' score of 0.00 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Telomir Pharmaceuticals	Neutral
Cartesian Therapeutics	Neutral

Summary

Cartesian Therapeutics beats Telomir Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to YD Bio?

YD Bio (NASDAQ:YDES) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

YD Bio's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
YD Bio	N/A	N/A	N/A
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
YD Bio	N/A	N/A	N/A	N/A	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A

In the previous week, YD Bio's average media sentiment score of 0.00 equaled Telomir Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
YD Bio	Neutral
Telomir Pharmaceuticals	Neutral

Summary

YD Bio and Telomir Pharmaceuticals tied by winning 2 of the 4 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Anavex Life Sciences?

Anavex Life Sciences (NASDAQ:AVXL) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.39	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A

Anavex Life Sciences' return on equity of -32.73% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-32.73%	-30.15%
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%

In the previous week, Anavex Life Sciences had 4 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 4 mentions for Anavex Life Sciences and 0 mentions for Telomir Pharmaceuticals. Anavex Life Sciences' average media sentiment score of 0.00 equaled Telomir Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Anavex Life Sciences	Neutral
Telomir Pharmaceuticals	Neutral

31.6% of Anavex Life Sciences shares are held by institutional investors. 11.4% of Anavex Life Sciences shares are held by insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Anavex Life Sciences has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market.

Anavex Life Sciences presently has a consensus target price of $21.33, suggesting a potential upside of 558.44%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Anavex Life Sciences is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Anavex Life Sciences beats Telomir Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

Get Telomir Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TELO vs. The Competition

Export

Metric	Telomir Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$77.72M	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-1.24	11.62	272.60	24.24
Price / Sales	N/A	1,338.17	618.96	99.81
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	16.14	16.80	13.05	6.20
Net Income	-$10.41M	-$12.50M	$3.47B	$348.59M
7 Day Performance	3.67%	3.29%	2.09%	0.08%
1 Month Performance	-2.59%	8.23%	6.64%	3.88%
1 Year Performance	-22.07%	55.05%	25.02%	16.98%

Telomir Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TELO Telomir Pharmaceuticals	0.4123 of 5 stars	$1.13 flat	N/A	-22.1%	$77.72M	N/A	N/A	1
CLLS Cellectis	1.951 of 5 stars	$3.17 +4.3%	$7.00 +120.8%	+19.3%	$318.08M	$79.59M	N/A	290	Positive News Gap Up
FATE Fate Therapeutics	2.7696 of 5 stars	$2.65 +3.5%	$5.90 +122.6%	+102.6%	$317.52M	$6.65M	N/A	550
RNAC Cartesian Therapeutics	2.1815 of 5 stars	$10.49 +14.0%	$32.60 +210.8%	-10.6%	$317.32M	$2.80M	N/A	64	Analyst Forecast High Trading Volume
YDES YD Bio	N/A	$4.47 +12.3%	N/A	N/A	$316.43M	$596.82K	N/A	N/A	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TELO) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Telomir Pharmaceuticals (TELO) Competitors

TELO vs. CLLS, FATE, RNAC, YDES, and AVXL

How does Telomir Pharmaceuticals compare to Cellectis?

Summary

How does Telomir Pharmaceuticals compare to Fate Therapeutics?

Summary

How does Telomir Pharmaceuticals compare to Cartesian Therapeutics?

Summary

How does Telomir Pharmaceuticals compare to YD Bio?

Summary

How does Telomir Pharmaceuticals compare to Anavex Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO vs. The Competition

Telomir Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Telomir Pharmaceuticals (TELO) Competitors

TELO vs. CLLS, FATE, RNAC, YDES, and AVXL

How does Telomir Pharmaceuticals compare to Cellectis?

Which has more risk and volatility, CLLS or TELO?

Do insiders & institutionals have more ownership in CLLS or TELO?

Is CLLS or TELO more profitable?

Which has higher valuation & earnings, CLLS or TELO?

Do analysts prefer CLLS or TELO?

Does the media favor CLLS or TELO?

Summary

How does Telomir Pharmaceuticals compare to Fate Therapeutics?

Do institutionals & insiders hold more shares of FATE or TELO?

Is FATE or TELO more profitable?

Do analysts recommend FATE or TELO?

Which has more risk and volatility, FATE or TELO?

Which has preferable valuation and earnings, FATE or TELO?

Does the media favor FATE or TELO?

Summary

How does Telomir Pharmaceuticals compare to Cartesian Therapeutics?

Do analysts rate TELO or RNAC?

Is TELO or RNAC more profitable?

Do insiders & institutionals hold more shares of TELO or RNAC?

Which has better earnings and valuation, TELO or RNAC?

Which has more volatility & risk, TELO or RNAC?

Does the media refer more to TELO or RNAC?

Summary

How does Telomir Pharmaceuticals compare to YD Bio?

Do analysts rate YDES or TELO?

Is YDES or TELO more profitable?

Which has stronger earnings & valuation, YDES or TELO?

Does the media favor YDES or TELO?

Summary

How does Telomir Pharmaceuticals compare to Anavex Life Sciences?

Which has preferable earnings and valuation, AVXL or TELO?

Is AVXL or TELO more profitable?

Does the media refer more to AVXL or TELO?

Do institutionals & insiders hold more shares of AVXL or TELO?

Which has more risk and volatility, AVXL or TELO?

Do analysts prefer AVXL or TELO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO vs. The Competition

Telomir Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools